Advik Laboratories is planning to raise funds by way of issue of one or more instruments including equity shares/ convertible securities or warrants on preferential basis at such price as may be determined in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to such approvals as may be required. A meeting of Board of Directors of the Company is scheduled to be held on April 15, 2022 to approve the same.
Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.
